In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa

Journal of Antibiotics

Volumn 68, Issue 9, 2015, Pages 551-555

  Di, Xiuzhen ^a   Wang, Rui ^a   Liu, Bin ^a   Zhang, Xin ^a   Ni, Wentao ^a   Wang, Jin ^a   Liang, Beibei ^a   Cai, Yun ^a   Liu, Youning ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CARBAPENEM RESISTANT PSEUDOMONAS AERUGINOSA; CHINA; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SENSITIVITY; IN VITRO STUDY; INFECTION CONTROL; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PSEUDOMONAS INFECTIONS;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; CHINA; COLISTIN; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; FOSFOMYCIN; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84942603594     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2015.27     Document Type: Article

References (25)

1. Kollef, M. H. Appropriate empiric antimicrobial therapy of nosocomial pneumonia: The role of the carbapenems. Respir Care. 49, 1530-1541 (2004).
2. Lautenbach, E. et al. Imipenem resistance in Pseudomonas aeruginosa: emergence, epidemiology, and impact on clinical and economic outcomes. Infect. Control Hosp. Epidemiol. 31, 47-53 (2010).
3. Souli, M., Galani, I. & Giamarellou, H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill. 13, 19045 (2008)
4. Giamarellou, H. & Poulakou, G. Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs 69, 1879-1901 (2009).
5. Falagas, M. E. & Rafailidis, P. I. Re-emergence of colistin in today's world of multidrugresistant organisms: personal perspectives. Expert Opin. Investig. Drugs 17, 973-981 (2008).
6. Michalopoulos, A. S. & Karatza, D. C. Multidrug-resistant Gram-negative infections: The use of colistin. Expert Rev. Anti Infect. Ther. 8, 1009-1017 (2010).
7. Yahav, D., Farbman, L., Leibovici, L. & Paul, M. Colistin: new lessons on an old antibiotic. Clin. Microbiol. Infect. 18, 18-29 (2012).
8. Petrosillo, N., Ioannidou, E. & Falagas, M. E. Colistin monotherapy vs. combination therapy: evidence from microbiological, animal and clinical studies. Clin. Microbiol. Infect. 14, 816-827 (2008).
9. Karageorgopoulos, D. E., Wang, R., Yu, X. & Falagas, M. E. Fosfomycin: Evaluation of the published evidence on the emergence of antimicrobial resistance in gram-negative pathogens. J. Antimicrob. Chemother. 67, 255-268 (2012).
10. Clinical and Laboratory Standards Insitute. Performance Standards for Antimicrobial Susceptebility Testing: Twenty-Third Informational Supplement. Report No. M100-S23 (CLSI, Wayne, PA, USA, 2013).
11. Magiorakos, A. P. et al. Multidrug-resistant, extensively drug-resistant and pandrugresistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 18, 268-281 (2012).
12. Moody, J. in Clinical Microbiology Procedures Handbook (ed. Isenberg, H. D.) 1-28 (ASW, Washington, DC, USA, 2004).
13. White, R. L., Burgess, D. S., Manduru, M. & Bosso, J. A. Comparison of three different in vitro methods of detecting synergy: Time-kill, checkerboard, and E test. Antimicrob. Agents Chemother. 40, 1914-1918 (1996).
14. Galani, I., Orlandou, K., Moraitou, H., Petrikkos, G. & Souli, M. Colistin/daptomycin: An unconventional antimicrobial combination synergistic in vitro against multidrugresistant Acinetobacter baumannii. Int. J. Antimicrob. Agents 43, 370-374 (2014).
15. Crusio, R. et al. Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy. Scand. J. Infect. Dis. 46, 1-8 (2014).
16. Garonzik, S. M. et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55, 3284-3294 (2011).
17. McCaughey, G., Diamond, P., Elborn, J.S., McKevitt, M. & Tunney, M. M. Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions. PLoS ONE 8, e69763 (2013).
18. Nakamura, T., Kokuryo, T., Hashimoto, Y. & Inui, K. I. Effects of fosfomycin and imipenem-cilastatin on the nephrotoxicity of vancomycin and cisplatin in rats. J. Pharm. Pharmacol. 51, 227-232 (1999).
19. Yanagida, C., Ito, K., Komiya, I. & Horie, T. Protective effect of fosfomycin on gentamicin-induced lipid peroxidation of rat renal tissue. Chem. Biol. Interact. 148, 139-147 (2004).
20. Sahuquillo Arce, J.M. et al. In vitro activity of linezolid in combination with doxycycline, fosfomycin, levofloxacin, rifampicin and vancomycin against methicillin-susceptible Staphylococcus aureus. Rev. Esp. Quimioter. 19, 252-257 (2006).
21. Samonis, G., Maraki, S., Karageorgopoulos, D. E., Vouloumanou, E. K. & Falagas, M.E. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur. J. Clin. Microbiol. Infect. Dis. 31, 695-701 (2012).
22. Markou, N. et al. Colistin serum concentrations after intravenous administration in critically ill patients with serious multidrug-resistant, Gram-negative bacilli infections: A prospective, open-label, uncontrolled study. Clin. Ther. 30, 143-151 (2008).
23. Roussos, N., Karageorgopoulos, D. E., Samonis, G. & Falagas, M. E. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections. Int. J. Antimicrob. Agents 34, 506-515 (2009).
24. Bergen, P. J. et al. Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob. Agents Chemother. 55, 5134-5142 (2011).
25. Rao, G.G. et al. New dosing strategies for an old antibiotic: pharmacodynamics of frontloaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease. Antimicrob. Agents Chemother. 58, 1381-1388 (2014).